Radionetics Oncology

About Radionetics Oncology

Radionetics Oncology is dedicated to advancing precision radiopharmaceuticals into a new era for the treatment of solid tumors. Their mission is to harness the power of radiation through targeted small molecule therapies to create effective cancer treatments, aiming to ultimately achieve a cure.

Products & Services

Small Molecule Radiopharmaceuticals:Targeted therapies using small molecules tethered with radioisotopes to bind to GPCRs overexpressed on cancer cells, delivering radiation directly to tumors.

Theranostic Radiopharmaceuticals:Dual-purpose drugs used for both therapy and diagnosis, enabling precise mapping of tumors and individualized treatment regimens.

Specialties

Precision Radiopharmaceuticals GPCR Targeting Small Molecule Drug Development Theranostics Cancer Treatment for Solid Tumors

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 52500000 MR: - FA: $52.5 million FAN: 52500000	D: 2024-01-05 FD: 2024-01-05	5 investors

Series A Latest

2024-01-05

$52.5M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Paul Grayson

Chief Executive Officer

A

Alyssa Levin

Chief Financial Officer

B

Brett Ewald

Chief Operating Officer

I

Istvan Molnar

Chief Medical Officer

F

Frank Zhu

Chief Research Officer

A

Ana Kusnetzow

Senior Vice President, Biology

View 18 more team members with Pro

Unlock Full Team Directory

Recent News